Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Predictive Model Helps Identify Those at Risk for Severe COVID-19

By HospiMedica International staff writers
Posted on 10 Mar 2021
A new predictive model can help identify those at risk for severe COVID-19, aiding in the fight against the global pandemic.

Researchers at the Buck Institute (Novato, CA, USA) analyzed data from the COVID-19 Symptom Tracker app used by three million people in the UK, adding the use of immunosuppressant medication, use of a mobility aid, shortness of breath, fever, and fatigue to the list of symptoms and comorbidities that increase the risk for severe COVID-19. More...
Out of the three million people who used the app, about 11,000 people tested positive for the virus and about 500 ended up in the hospital.

The symptom-tracking app collects data from multiple angles, asking people to describe how they feel, symptoms they are experiencing, and medications they are using along with demographics and lifestyle factors such as nutrition and diet. The results did not identify chronological age as a risk factor for severe COVID-19 and the fact that elderly people are less likely to use a smartphone app was a limitation of the study. However, many of the factors identified in the study are related to aging. Additionally, the findings identified the use of immunosuppressant medications as a major predictor of more serious disease warrant more investigation.

“Are these patients doing worse because of an underlying auto-immune/auto-inflammatory disease or because the medications are suppressing their inflammatory response – we don’t know,” said Buck Institute Associate Professor David Furman, PhD, the senior scientist who led the study. “Labs around the world are studying the overactive immune response that leads to the cytokine storm which is associated with severe COVID-19. Our findings highlight the need to understand the biology of what is at play in these cases.”

Furman and colleagues are using artificial intelligence and machine learning to pursue other COVID-related research. Efforts are underway to predict patients likely to become COVID “long haulers” – those who experience ongoing debilitating symptoms long after they recover from acute disease. Researchers are also correlating earlier data that identified aging phenotypes within individual proteomes (the entire complement of proteins expressed within our cells and tissues) with the proteomes of those infected with the coronavirus. Furman says preliminary data suggests that there is a subgroup of COVID-19 patients who are aging faster in regards to their proteome. He says the hope is to identify interventions that would restore their protein expression to a younger state.

Related Links:
Buck Institute


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.